Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views
null
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
null
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)
null
Compugen Q1 Earnings Call Highlights
null
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner...
null
Compugen Reports First Quarter 2026 Results
null
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
null
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
null
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
null
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
null
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered...
null
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
null
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
null
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
null
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery...
null
Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference
null
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
null
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
null
Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year
null
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
#Product Stage #Partners #Investment
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
undefined
Compugen Reports Fourth Quarter and Full Year 2025 Results
#Product Stage #Partners #Management Changes
Compugen: Q4 Earnings Snapshot
undefined
Compugen Ltd. Q4 2025 Earnings Call Summary
null
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending...
#Product Stage #Partners #Management Changes #Investment
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
undefined
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
undefined
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
undefined
Compugen to Participate in Upcoming Investor Conferences
#Product Stage #Partners
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
#Product Stage #Partners #Public Trading
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery...
#Product Stage #Partners
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
#Management Changes #Partners
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery...
#Management Changes #Partners
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
#Partners #Investment
Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
#Product Stage #Partners #Customers
Compugen: Q3 Earnings Snapshot
undefined
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform...
#Product Stage #Partners #Investment
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
undefined
Compugen Reports Third Quarter 2025 Results
#Product Stage #Partners
Compugen (NASDAQ:CGEN) Is In A Strong Position To Grow Its Business
undefined
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
undefined
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
#Product Stage #Partners
Compugen to Participate in Stifel 2025 Healthcare Conference
#Product Stage #Partners
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
undefined
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
#Product Stage #Partners
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
#Product Stage #Partners
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
#Product Stage #FDA approved/pending approval
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
#Product Stage #Partners
Compugen to Present at SITC 2025
#Product Stage #Partners
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
#Partners
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
undefined
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
#Product Stage
BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support
#Partners
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
#Partners
Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility
undefined
Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes
undefined
Compugen to Present Research at the Single Cell Genomics 2025 Conference
#Product Stage #Partners
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
#Product Stage #Partners
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
undefined
Compugen Reports Second Quarter 2025 Results
#Product Stage #Partners
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
undefined
Compugen: Q2 Earnings Snapshot
undefined
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
#Product Stage #Partners
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
#Product Stage #Partners
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
#Product Stage #Partners
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
#Product Stage
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
#Product Stage #Partners
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
undefined
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
#Product Stage #Partners
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Product Stage #Partners
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
undefined
Compugen First Quarter 2025 Earnings: Misses Expectations
undefined
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
#Product Stage #Partners #Customers
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
undefined
Compugen Reports First Quarter 2025 Results
#Product Stage #Partners #Management Changes
Compugen: Q1 Earnings Snapshot
undefined
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human...
#Product Stage #Partners #Management Changes
Compugen Announces Leadership Transitions Effective September 2025
#Management Changes #Partners
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
#Product Stage #Partners
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
#Product Stage #Partners
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts
undefined
Calculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)
undefined
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
#Product Stage #Investment #Customers
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
undefined
/C O R R E C T I O N -- Compugen Ltd./
#Product Stage #Partners
Compugen: Q4 Earnings Snapshot
undefined
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
#Product Stage #Partners
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing...
#Partners
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
#Partners
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Product Stage #Partners
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
#Product Stage #Partners
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
#Product Stage #Partners
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Product Stage #Partners
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
#Product Stage #Partners
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable
undefined
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
undefined
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
undefined
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
undefined
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
#Customers #Partners
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in...
#Partners #Investment
Compugen Reports Third Quarter 2024 Results
#Partners #Expand
Compugen: Q3 Earnings Snapshot
undefined
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
undefined
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
undefined
Compugen to Participate in Stifel 2024 Healthcare Conference
undefined
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
undefined
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
undefined
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
#Customers #Partners
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Partners
Compugen to Present New Clinical Data at SITC 2024
#Partners
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
undefined
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Partners
Compugen to Present at Single Cell Genomics 2024 Conference
#Partners
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
#Partners
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
#Partners
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
undefined
Party Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings Forecasts
#None
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
#Investment
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
undefined
Compugen Reports Second Quarter 2024 Results
#Partners #Investment
Compugen: Q2 Earnings Snapshot
#Investment
Compugen receives FDA approval for Phase I trial of solid tumour treatment
#Investment #Partners
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
#Investment #Partners
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
#Public Trading
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
#Customers #Management Changes
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
#Customers #Investment
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
#Customers #Layoffs
The past three years for Compugen (NASDAQ:CGEN) investors has not been profitable
#Public Trading
Compugen to Present at Upcoming Antibody Industrial Symposium
#Partners, Customers
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
undefined
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
#Partners #Investment
Earnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00
#Customers
Compugen Reports First Quarter 2024 Results
#Customers #Partners #Investment
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
#Management Changes
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
#Investment, Partners
Compugen Appoints David Silberman as Chief Financial Officer
#Management Changes
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
#Public Trading
We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
#Investment
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
#Customers #Partners
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
#Investment #Partners
Compugen to Participate in Two Upcoming Investor Conferences
#Investment
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?
#Investment
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
#Investment
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
#Customers, Partners
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
#Management Changes #Investment #Partners
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
#Customers, Partners
Compugen Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
#Customers, Investment
Compugen Reports Fourth Quarter and Full Year 2023 Results
#Partners #Investment
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
#Investment
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
#Customers, Investment
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
#Management Changes
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
#Investment
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
#Public Trading
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
#Management Changes
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
#Partners #Investment
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
#Partners, Investment, Management Changes
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
undefined
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
#Partners #Investment
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
#Partners #Investment
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
null
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
#Partners
Compugen shares soar on massive deal with Gilead, worth up to $848 million | CTech
#Partners #Investment
7 Promising Penny Stocks With the Potential to Defy Expectations
#Investment
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
#Public Trading
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
#Investment
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript
#Management Changes #Customers
Compugen Reports Third Quarter 2023 Results
#Investment
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
#Investment #Partners
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
#Public Trading
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
#Investment, Expand
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
undefined
Compugen to Present at Single Cell Genomics 2023 Meeting
#Customers #Partners
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
#Customers
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
undefined
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
#Investment
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
#Public Trading
Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?
#Customers
Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript
#Management Changes #Investment
Compugen Reports Second Quarter 2023 Results
#Customers #Partners #Management Changes
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
#Public Trading
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
#Customers
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
#Customers
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
#Customers #Partners
We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully
#Investment
Cathie Wood is Selling These 12 Stocks in 2023
#Investment
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
#Investment #Customers
Compugen Reports First Quarter 2023 Results
#Investment
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
#Investment
Compugen to Present at the JMP Securities Life Sciences Conference
undefined
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
#Public Trading
Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023
#Partners #Customers
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
#Investment #Expand
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
#Customers
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
undefined
Compugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past week
undefined
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript
#Partners #Investment
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
#Management Changes
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study
#Customers #Partners
Why Compugen Shares Are Up Today
undefined
Compugen Reports Fourth Quarter and Full Year 2022 Results
#Investment
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
#Expand
Compugen changes drug discovery business strategy - News Bit
#Partners #Investment
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
#Partners
לא רק חיסכון בהוצאות: קומפיוג'ן מסיימת את ההסכם עם BMS
#Partners #Layoffs
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
#Partners #Expand
Bristol Myers Squibb invests $20m in Compugen cancer drug
#Investment
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
#Partners #Expand
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
#Customers #Partners
"2021 תהיה שנה חשובה ומרובת אבני דרך עבור קומפיוגן"
#Investment
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
#Partners #Expand
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
#Partners #Expand
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody P...
undefined
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
#Partners
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
#Partners
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
#Investment
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
#Partners #Investment
Compugen makes equity offering
#Investment
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
#Customers
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
#Partners
Compugen expands agreement with BMS
#Partners #Expand
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
#Investment
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
#Investment
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
#Management Changes
Compugen Added to the NASDAQ Biotechnology Index
#Public Trading
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
undefined
https://www.jpost.com/HEALTH-SCIENCE/Israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors-606918
#Customers #Partners #Investment
Compugen Announces FDA Clearance of IND Application for COM902
#Investment #Expand
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
#Partners #Investment
Compugen Appoints Eran Perry to Its Board of Directors
#Management Changes
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
#Partners #Investment
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
#Partners #Investment
Compugen reports revenue, announces restructuring
#Layoffs
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
#Partners #Investment
Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
#Partners #Investment
BMS invests $12m in Compugen for tumor collaboration
#Investment
Compugen earns $7.8m payment from Bayer
#Investment
Compugen signs cancer drug licensing deal worth up to $200m
#Partners #Investment
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
#Partners #Investment
Compugen reports positive cancer therapy results
#Expand
Publications - Compugen
#Partners #Customers